Whether in HR+ or HR− subtype, HER2-positive breast cancer was characterized by gains in 17q12 (ERBB2, CDK12, HNF1B, RAD51D), and almost no gains of 17q12 were present in the other subtypes. Here, RAD51D is linked to breast carcinoma.